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Exercise capacity in patients with left heart failure is 
closely related to the performance of the right ventricle 
and the pulmonary circulation. To determine the sig-
nificance of changes in pulmonary resistance during long-
term vasodilator therapy, hemodynamic studies were 
performed before and after 1 to 3 months of treatment 
with captopril in 75 patients with severe chronic left 
heart failure. 
Patients were grouped according to the relative 
changes in pulmonary and systemic resistances during 
long-term therapy: patients in Group I (n = 24) showed 
greater decreases in pulmonary arteriolar resistance (PAR) 
than in systemic vascular resistance (SVR) (% .:1 PAR/% 
.:1 SVR > 1.0), whereas patients in Group II showed 
predominant systemic vasodilation (% .:1 PAR/% .:1 SVR 
< 1.0). Despite similar changes in systemic resistance, 
patients in Group I showed greater increases in cardiac 
index, stroke volume index and left ventricular stroke 
work index (p < 0.01 to 0.001) but less dramatic de-
creases in mean systemic arterial pressure (p < 0.02) 
than did patients in Group II. Despite similar changes 
Inhibition of the angiotensin-converting enzyme with cap-
topril is an established approach to the treatment of patients 
with severe chronic heart failure (1), Randomized placebo-
controlled trials (2,3) have shown that long-term therapy 
with captopril produces hemodynamic and symptomatic 
benefits that are accompanied by significant increases in 
exercise tolerance. Captopril also preferentially increases 
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in left ventricular filling pressure, patients in Group I 
showed greater decreases in mean pulmonary artery and 
mean right atrial pressures (p < 0.02 to 0.01) than did 
patients in Group II. Pretreatment variables in Groups 
I and II were similar, except that plasma renin activity 
was higher (8.7 ± 2.1 versus 3.0 ± 0.6 ng/ml per h) 
and serum sodium concentration was lower (133.1 ± 
0.9 versus 137.1 ± 0.6 mEq/liter) in Group II than in 
Group I (both p < 0.05). Both groups improved clinically 
after 1 to 3 months, but symptomatic hypotension oc-
curred more frequently in Group II than in Group I (3~ 
versus 8%) (p < 0.005). 
These findings indicate that changes in the pulmonary 
circulation modulate alterations in both right and left 
ventricular performance during the treatment of pa-
tients with left heart failure. Hyponatremic patients are 
likely to experience symptomatic hypotension with cap-
topril because they are limited in their ability to increase 
cardiac output as a result of an inadequate pulmonary 
vasodilator response to the drug. 
(J Am Coll CardioI1985;6:635-45) 
renal and cerebral blood flow and favorably modifies salt 
and water homeostasis (4-9), and these actions may con-
tribute significantly to the therapeutic effects of the drug. 
Because excessive systemic resistance has been regarded 
as the principal hemodynamic abnormality in patients with 
heart failure, previous studies of captopril have focused 
largely on its effects on the systemic vasculature and left 
ventricle, and little attention has been given to its actions 
on the pulmonary circulation. Recent evidence (10, II) in-
dicates, however, that exercise capacity in patients with left 
heart failure is more closely related to the performance of 
the right ventricle than that of the left ventricle, because the 
pulmonary circulation fails to dilate significantly in these 
patients during exertion and may thereby limit any increase 
in cardiac output that might be expected to follow a decrease 
in resistance to left ventricular ejection. Therefore, treat-
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ment with systemic vasodilator drugs may not increase for-
ward flow and exercise capacity if the decrease in pulmonary 
resistance fails to match the decrease in systemic resistance 
(12), but fortunately, most vasodilating agents dilate the 
systemic and pulmonary circulations to a similar degree 
(13-15). Such a balanced effect may not occur during con-
verting enzyme inhibition, however, because angiotensin 
exerts little direct constrictor effect on the pUlmonary circuit 
in doses that markedly affect systemic vessels (16-20). 
Therefore, short-term treatment with captopril in patients 
with heart failure produces decreases in pulmonary resis-
tance that are less marked than the concomitant decreases 
in systemic resistance (21,22). Whether this hemodynamic 
discordance persists during long-term therapy with the drug, 
however, remains unknown. In the present study we eval-
uated the long-term changes in pulmonary arteriolar resis-
tance in patients with severe left ventricular failure treated 
with captopril to determine their hemodynamic and clinical 
significance and to postulate potential mechanisms that may 
underlie the occurrence of these changes. 
Methods 
Study patients. The study group consisted of 75 con-
secutive patients with severe chronic heart failure treated 
with captopril who underwent invasive hemodynamic stud-
ies during short- and long-term treatment with the drug. All 
patients had dyspnea and fatigue at rest or on minimal ex-
ertion despite optimal therapy with digitalis and diuretic 
drugs; all had a left ventricular ejection fraction less than 
30% by radionuclide angiography. There were 55 men and 
20 women, aged 28 to 83 years (mean 64). The cause of 
heart failure was ischemic heart disease in 46 patients, pri-
mary dilated cardiomyopathy in 23 patients and primary 
mitral or aortic valve regurgitation, or both, in 6 patients, 
3 of whom had undergone valve replacement surgery. No 
patient had had an acute myocardial infarction within 4 
weeks or an acute exacerbation of symptoms of heart failure 
within 2 weeks. 
Hem9dynamic assessmt!nt. Each patient received cap-
topril under controlled study conditions for 1 to 3 months, 
during which time the hemodynamic effects of the drug 
were assessed by right heart catheterization performed be-
fore initiation of therapy and at the end of the treatment 
period. At the beginning of the trial, for at least 5 days 
before administration of captopril, doses of digoxin and 
diuretic drugs remained constant, all previous vasodilator 
drugs were discontinued and patients maintained stable weight 
while consuming a 2 g sodium diet. After completion of 
this initial stabilization period, right heart catheterization 
and arterial cannulation were performed for measurement 
of intracardiac and systemic pressures, respectively (9,15,21). 
Left ventricular filling pressure was estimated from the mean 
pulmonary capillary wedge pressure (71 patients) or from 
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the pulmonary artery diastolic pressure after its identity with 
wedge pressure was established (4 patients). Thermodilution 
cardiac outputs were determined in triplicate by a bedside 
cardiac output computer using iced injectate. 
Drug administration. The following hemodynamic 
variables were measured repeatedly for at least 2 hours (with 
a variation of less than 10%) to ensure stability of the pre-
treatment hemodynamic state before drug administration: 
mean arterial pressure, heart rate, left ventricular filling 
pressure, mean right atrial pressure and cardiac output. Each 
patient then received an initial dose of 25 mg of captopril 
orally followed by long-term therapy with the drug. Because 
the response to converting enzyme inhibition is not dose 
dependent (23,24), the doses of captopril prescribed for 
long-term treatment were based on each patient's renal func-
tion: patients with a serum creatinine concentration less than 
2.0 mg/dl generally received 150 to 300 mg orally daily, 
whereas patients with higher concentrations received 75 to 
150 mg orally daily. For the next 1 to 3 months, doses of 
digitalis, diuretic agents and captopril remained unaltered, 
and a 2 g sodium diet was maintained. At the end of the 
treatment period, patients were again hospitalized for a 5 
day stabilization period, after which right heart catheteriza-
tion and arterial cannulation were again performed to assess 
the long-term response to treatment. The protocol for the 
second evaluation was identical in all respects to that of the 
first study. 
During the first hemodynamic study, all hemodynamic 
variables determined during the baseline period were reas-
sessed every 30 minutes for 3 hours after administration of 
the first 25 mg dose of captopril; during the second hemo-
dynamic study, these variables were measured at identical 
intervals after administration of the same dose of captopril 
each patient had been receiving during the previous 1 to 3 
months. 
Additional pharmacologic testing was performed in se-
lected patients during the second hemodynamic study after 
the long-term effects of captopril had been assessed. In nine 
patients in whom captopril produced minimal changes in 
pulmonary arteriolar resistance, nitroglycerin (0.4 mg sub-
lingually) was administered 30 to 60 minutes after the peak 
effect of captopril was observed, and aU hemodynamic vari-
ables were reassessed every 2 to 5 minutes for 20 to 30 
minutes. 
Biochemical and clinical determinations. Blood sam-
ples were collected just before initiation of captopril therapy 
for determination of blood urea nitrogen and serum creat-
inine concentration in all patients and for measurement of 
plasma renin activity in 71 of the 75 patients; these variables 
were reassessed during the second hemodynamic study 90 
minutes after captopril administration. All samples were 
drawn at the same time of day, while patients were con-
suming a 2 g sodium diet, and after at least 4 hours in the 
supine position. 
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Changes in the clinical status of each patient after 1 to 
3 months of treatment with captopril were assessed in re-
lation to symptoms of dyspnea and fatigue at rest and ex-
ercise tolerance. Because all patients had symptoms at rest 
or on minimal exertion, formal exercise testing was not 
performed. 
Data analysis. Mean systemic and pulmonary artery 
pressures were determined by electronic filtration. Derived 
hemodynamic variables were calculated as follows: cardiac 
index (CI) = CO/body surface area (liters/min per m2); 
stroke volume index (SVI) = CIIHR (beats/min); LV stroke 
work index = (MAP - LVFP) x SVI x 0.0136 (g.mlm2); 
RV stroke work index = (MPAP - MRAP) x SVI x 
0.0136 (g.mlm2); systemic vascular resistance (SVR) = 
80 x (MAP - MRAP)/CO (dynes.s-cm- 5); pulmonary ar-
teriolar resistance (PAR) = 80 x (MPAP - LVFP)/CO 
(dynes.s.cm - 5), where CO = cardiac output, HR = heart 
rate, LV = left ventricular, R V = right ventricular, MAP 
= mean systemic arterial pressure, L VFP = left ventricular 
filling pressure, MPAP = mean pulmonary artery pressure 
and MRAP = mean right atrial pressure. 
The hemodynamic effects of captopril during the first 
and second hemodynamic studies were assessed at its peak 
effect on left ventricular filling pressure and mean systemic 
arterial pressure (60 ± 30 minutes after drug administra-
tion). The hemodynamic responses seen during short- and 
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long-term therapy in our 75 patients were compared with 
the pre-captopril hemodynamic state (Table 1) by a repeated 
measures analysis of variance procedure, in which Duncan's 
multiple range test was used to differentiate among signif-
icant responses. 
Patients were then classified into three groups according 
to the hemodynamic responses observed during long-term 
treatment: Patients in Group I showed predominant pul-
monary vasodilation, as evidenced by a percent decrease in 
pulmonary arteriolar resistance (PAR) that was greater than 
the percent decrease in systemic vascular resistance (SVR) 
(% ~ PAR/% ~ SVR > 1.0) with both variables decreasing 
by at least 20%; this definition is similar to those we and 
other investigators utilized to identify an active pulmonary 
vasodilator response in previous studies (25-27). Patients 
in Group II showed predominant systemic vasodilation, as 
evidenced by a % ~ PAR/% ~ SVR less than 1.0, with 
both variables decreasing by at least 20%. Patients in whom 
neither systemic vascular resistance nor pulmonary arteriolar 
resistance decreased at least 20% during long-term treatment 
were identified as Group III. 
Statistics. The control hemodynamic, biochemical and 
hormonal variables before captopril administration in the 
three groups were compared by one-way analysis of variance 
followed by the t test for independent variables to differ-
entiate among significant responses. Qualitative differences 
Table 1. Short- and Long-Term Hemodynamic Effects of Captopril in 75 Patients With Severe 
Chronic Heart Failure 
C 01 LT P Value 
Cardiac index 1.78 2.07* 2.03* NS 
(liters/min per m2 ) ±0.05 ±0.06 ±0.05 
Stroke volume index 21.8 27.7* 27.8* NS 
(ml/beat per m2) ±0.8 ± 1.0 ±0.9 
Heart rate 85.4 78.0* 75.9* NS 
(beats/min) ± 1.8 ± 1.8 ± 1.8 
Left ventricular filling 26.8 17.9* 16.0* < 0.05 
pressure (mm Hg) ±0.6 ±0.7 ±0.9 
Mean systemic arterial 83.9 67.1 * 67.8* NS 
pressure (mm Hg) ± 1.6 ± 1.8 ± 1.8 
Mean pulmonary artery 40.8 31.6* 28.8* < 0.01 
pressure (mm Hg) ±0.8 ±0.8 ± 1.0 
Mean right atrial 11.5 8.3* 6.6* < 0.01 
pressure (mm Hg) ±0.7 ±0.6 ±0.7 
Systemic vascular 2,003 1,442* 1,465* NS 
resistance (dynes·s·cm 5) ±75 ±79 ±58 
Pulmonary arteriolar 393 333* 310* NS 
resistance (dynes's'cm- s) ±21 ±17 ± 15 
Right ventricular stroke 8.6 8.5 8.3 NS 
work index (g'mim2) ±0.4 ±0.4 ±0.4 
Left ventricular stroke 16.7 18.3t 19.8* < 0.05 
work index (g'm/m2) ±0.9 ±0.8 ± 1.0 
Symbols indicate significance of difference from pre-captopril values: *p < 0.01, tp < 0.05. Values for 
p indicate significance of 01 versus LT, where C = control (pre-captopril); 01 = first captopril dose; LT = 
long-term captopril therapy (I to 3 months). 
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among the three groups were assessed by the chi-square 
statistic. The long-term biochemical and hormonal effects 
of captopril were compared with pretreatment values within 
each group by the t test for paired data and among the three 
groups by analysis of variance. The hypotheses that two 
variables were related were tested by least squares linear 
regression analysis. The responses to nitroglycerin in nine 
patients were assessed and compared with the effects of 
captopril in these patients by a repeated measures analysis 
of variance procedure similar to tha~ utilized for Table 1. 
All group data are expressed as mean ± SEM. 
Results 
Overall short- and long-term hemodynamic responses 
(Table 1). In our 75 patients with severe chronic heart 
failure, captopril produced significant increases in cardiac 
index, stroke volume index and left ventricular stroke work 
index and significant decreases in left ventricular filling 
pressure, mean pulmonary and systemic arterial pressures, 
mean right atrial pressure and systemic and pulmonary re-
sistances during short- and long-term therapy (p < 0.01) 
without significant changes in right ventricular stroke work 
index. During the course of treatment, we noted a progres-
sive increase in left ventricular stroke work index and a 
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progressive decrease in left ventricular filling pressure, mean 
pulmonary artery pressure and mean right atrial pressure 
(p < 0.05 to 0.01), whereas other hemodynamic variables 
generally remained at levels similar to those seen after the 
first dose of the drug. 
After the first doses of captopril, the magnitude of the 
decrease in pulmonary arteriolar resistance was substantially 
less than the magnitude of the qecrease in systemic vascular 
resistance (15 versus 28%, p < 0.001), and this discordance 
persisted during long-term treatment with the drug. There 
was a significant relation between the magnitude of the 
decrease in pulmonary arteriolar resistance after the first 
dose of captopril and the decrease in this variable after 1 
to 3 months of therapy in individual patients (r == 0.57, 
P < 0.001). 
. Intergroup differences in the hemodynamic response 
to captopril (Table 2). Patients in Groups I, II and III were 
similar with respect to all pretreatment hemodynamic vari-
ables, except that patients in Group III had a significantly 
lower mean pulmonary artery pressure and pulmonary ar-
teriolar resistance than did patients in Groups I and II (whose 
pretreatment hemodynamic state was similar with respect 
to all measured variables). The hemodynamic responses to 
long-term captopril therapy in patients in Groups I and II 
are shown and compared in Figures 1 to 3. In patients in 
Table 2. Pretreatment Hemodynamic and Clinical Variables in Patient Subsets 
Group I Group II Group III 
(n = 24) (n = 28) (n = 23) p Value 
Age (yr) 65.5 :!: 1.9 61.9 :!: 2.6 63.7 :!: 2.8 NS 
Sex (M/F) 2113 19/9 15/8 NS 
CHF etiology ICM(l6), POC(6), VR(2) ICM(l9), POC(6), VR(3) ICM(lI), POC(I)), VR(I) NS 
Weight (kg) 69.1 :!: 2.5 62.1 :!: 2.9 64.7 :!: 2.3 NS 
BUN (mg/dl) 33.2 :!: 3.4 47.8 :!: 6.8 45.7 :!: 7.5 NS 
Serum Cr (mg/dl) 1.5 :!: 0.1 1.7 :!: 0.1 2.0 :!: 0.4 NS 
PRA (ng/ml per h) 3.0 :!: 0.6 8.7 :!: 2.1 2.5 :!: 0.7 < 0.01 
Serum Na (mEq/liter) 137.1 :!: 0.6 133.1 :!: 0.9 136.0 :!: 0.6 < 0.01 
CI (liters/min per m2) 1.74 :!: 0.09 1.70 :!: 0.06 1.92 :!: 0.11 NS 
SVI (ml/beat per m2) 20.6:!: 1.3 20.5 :!: 1.2 24.6:!: 1.6 NS 
HR (beats/min) 87.2 :!: 2.8 88.0 :!: 3.2 79.9 :!: 2.9 NS 
MAP (mm Hg) 86.7 :!: 2.8 81.3 :!: 1.7 84.3 :!: 3.8 NS 
LVFP (mm Hg) 27.1 :!: 0.9 26.8 :!: 1.1 26.5 :!: 1.3 NS 
MPAP (mm Hg) 43.6 :!: 1.2 40.5 :!: 1.4 38.3 :!: 1.5 < 0.05 
MRAP (mm Hg) 12.0 :!: 1.2 11.0 :!: 1.2 11.5 :!: 1.3 NS 
SVR (dynes·s·cm- 5) 2,002 :!: 126 2,075 :!: 110 1,926 :!: 164 NS 
PAR (dynes.s'cm- 5) 459 :!: 48 407 :!: 27 308 :!: 27 < 0.02 
RVSWI (g'mlm2) 8.8 :!: 0.7 8.2 :!: 0.6 8.8 :!: 0.6 NS 
L VSWI (g'mlm2) 16.8 :!: 1.5 15.2 :!: 1.1 18.4 :!: 1.9 NS 
Group I = patients with predominant pulmonary vasodilation; Group II = patients with predominant systemic vasodilation; Group III = patients 
with neither systemic nor pUlmonary vasodilation. Values for p indicate significance among the three groups by analysis of variance. The significance 
of plasma renin ;lctivity (PRA) and serum sodium (Na) results from differences between Group II and the other two groups; the significance of mean 
pUlmonary artery pressure (MPAP) and pulmonary arteriolar resistance (PAR) results from differences between Group III and the other two groups. 
BUN = blood urea nitrogen; CHF = congestive heart failure; q = cardiac index; Cr = creatinine; F = female; HR = heart rate; ICM = ischemic 
cardiomyopathy; L VFP = left ventricular filling pressure; L VSWI = left ventricular stroke work index; M = male; MAP = mean systemic arterial 
pressure; MRAP = mean right atrial pressure; POC = primary dilated cardiomyopathy; RVSWI = right ventricular stroke work index; SVI = stroke 
volume index; SVR = systemic vascular resistance; VR = valvular regurgitation. 
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Figure 1. Changes in cardiac index, mean systemic arterial pres-
sure and systemic vascular resistance during long-term captopril 
therapy in patients in Group I (predominant pulmonary vasodila-
tion) and Group II (predominant systemic vasodilation). Asterisks 
indicate significance of captopril effect from pretreatment values 
within each group (*p < 0.001); P values at the top of each panel 
indicate significance of differences in the long-term responses be-
tween the two groups. Group data expressed as mean ± SEM. 
Groups I and II, captopril produced similar decreases in 
systemic vascular resistance (- 34 versus - 35%, respec-
tively), whereas, by definition, Group I showed significantly 
greater decreases in pulmonary arteriolar resistance than did 
Group II (-45 versus -18%, p < 0.001). Consequently, 
cardiac index increased (+0,54 versus + 0.23 liter/min 
per m2 , p < 0.001) and mean pulmonary artery pressure 
decreased (-18.1 versus -12.7 mm Hg, p < 0.02) to a 
greater degree in Group I than in Group II. 
The difference noted between Groups I and II with re-
spect to cardiac index was not due to different effects of 
captopril on heart rate in the two groups; heart rate decreased 
significantly (p < 0.001) and similarly in both cohorts 
(87.2 ± 2.8 to 76.3 ± 2.8 beats/min in Group I and 88.0 
± 3.2 to 76.2 ± 3.1 beats/min in Group II). Therefore, 
Figure 2. Changes in mean pulmonary artery pressure, mean right 
atrial pressure and pulmonary arteriolar resistance during long-
term captopril therapy in patients in Groups I and II. Format and 
symbols as in Figure 1. 
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Figure 3. Changes in stroke volume index, left ventricular (LV) 
stroke work index and left ventricular filling pressure during long-
term captopril therapy in patients in Groups I and II. Format and 
symbols as in Figure I. 
stroke volume index ( + 10.0 versus + 6.1 mllbeat per m2 , 
p < 0.01) and left ventricular stroke work index (+6,7 
versus + 1.2 g.mlm2 , p < 0.001) increased more in Group 
I than in Group II. The small increase in left ventricular 
stroke work index seen in patients in Group II was not 
significant. Because the decrease in systemic vasc~lar re-
sistance in the two groups was similar and the increase in 
cardiac index in patients in Group I was greater than in 
Group II, mean systemic arterial pressure decreased less in 
patients with predominant pulmonary vasodilation than in 
those with predominant systemic vasodilation (Group I ver-
sus Group II, -16.4 versus -21.7 mm Hg, respectively; 
p < 0.02). 
Left ventricular filling pressures decreased similarly in 
both groups, but because pulmonary arteriolar resistance 
decreased more in Group I than in Group II, patients in 
Group I showed a greater decrease in mean right atrial 
pressure than did those in Group II ( - 8.0 versus - 4.1 mm 
Hg, P < 0.0 I). Although right ventricular stroke work index 
increased slightly in Group I and decreased slightly in Group 
II, these changes did not reach statistical significance. 
Patients in Group III showed small but significant (p < 
0.05) increases in stroke volume index and decreases in left 
ventricular filling pressure, mean pulmonary artery pressure, 
mean right atrial pressure and systemic vascular resistance 
without changes in cardiac index, right or left ventricular 
stroke work index or pulmonary arteriolar resistance (data 
not shown). The magnitude of these changes (where sig-
nificant) was less than the changes seen in Groups I and II 
for all hemodynamic variables (p < 0.05 to 0.01). 
Intergroup differences in the hormonal and clinical 
response to captopril (Tables 2 and 3). Patients in Groups 
I, II and III were similar with respect to age, sex, cause of 
heart failure, pretreatment body weight and pretreatment 
renal function. Pretreatment values for plasma renin activ-
ity, however, were significantly higher in patients in Group 
II (8.7 ± 2.1 ng/ml per h) than in Groups I and III 
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Table 3. Changes in Biochemical and Hormonal Variables During Long-Term Captopril Therapy in Specific Patient Subsets 
Group I Group II Group III 
C CPT C CPT C CPT P Value 
Body weight (kg) 69.1 67.2* 62.1 62.6 64.7 63.7 < 0.05 
±2.5 ±2.3 ±2.9 ±2.9 ±2.3 ±2.2 
Blood urea 33.2 44.0 47.8 56.1 45.7 51.0 NS 
nitrogen (mg/dl) ±3.4 ±6.4 ±6.8 ±7.1 ±7.5 ±7.6 
Serum creatinine 1.5 1.6 1.7 1.8 2.0 2.1 NS 
concentration (mg/dl) ±O.I ±0.2 ±O.I ±O.I ±0.4 ±0.3 
Plasma renin 3.0 21.7* 8.7 17.0* 2.5 10.7* < 0.05 
activity (ng/ml per h) ±0.6 ±4.9 ±2.1 ±2.3 ±0.7 ± 1.8 
*Significance of change (p < 0.01) during long-term captopril therapy within each group. Values for p in the last column signify significance of 
differences among the three groups (by analysis of variance) in the magnitude of captopril-induced changes; with respect to weight and plasma renin 
activity, the observed significance is the result of changes in Group I that were greater in magnitude than those seen in Groups II and III. C = control; 
CPT = I to 3 months of captopril therapy. 
(3,0 ± 0,6 and 2.5 ± 0.7 ng/ml per h, respectively, both 
p < 0.05 versus Group II). Accordingly, values for serum 
sodium concentration were lower in patients in Group II 
(133.1 ± 0.9 mEg/liter) than in Groups I and III (137.1 
± 0.6 and 136.0 ± 0.6 mEg/liter, respectively; p < 0.01 
and 0.05 versus Group II, respectively). Considering only 
patients in Groups I and II (in whom systemic vascular and 
pulmonary arteriolar resistance both decreased), we noted 
a linear but inverse relation between the pretreatment plasma 
renin activity (PRA) and the ratio of the change in pul-
monary to the change in systemic resistance during long-
term captopril therapy (PRA versus % d PAR/% d SVR; 
r = 0.53; P < 0.001) (Fig. 4). 
Changes in biochemical and hormonal variables in the 
three groups of patients before and after captopril are shown 
in Table 3. Plasma renin activity increased significantly 
(p < 0.01) in all three groups of patients; the magnitude of 
reactive hyperreninemia in patients in Group I ( + 18.7 ± 
4.9 ng/ml per h), however, was significantly greater than 
Figure 4. Relation between the ratio of the change in pulmonary 
arteriolar resistance to the change in systemic vascular resistance 
(% .:l PAR/% .:l SVR) during long-term captopril therapy to pre-
treatment values for plasma renin activity in individual patients in 
Groups I and II who showed a decrease in both pulmonary and 
systemic resistance. 
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in Group II (+ 8.3 ± 2.7 ng/ml per h) and in Group III 
(+ 8.2 ± 1.7 ng/ml per h, both p < 0.05 versus Group I). 
Body weight decreased during the course of captopril ther-
apy only in patients in Group I (69.1 ± 2.5 to 67.2 ± 2.3 
kg, P < 0.01), whereas there was no significant change in 
weight in the other two groups. Blood urea nitrogen and 
serum creatinine concentration failed to change significantly 
in any of the three groups. 
With respect to clinical response during the course of 
long-term captopril therapy, 19 (79%) of 24 patients in 
Group 1,20 (71 %) of 28 patients in Group II and 11 (48%) 
of 23 patients in Group III improved clinically by at least 
one New York Heart Association functional class (Group 
III versus the other two groups, p < 0.05). Therapy was 
complicated by symptomatic hypotension, however, in 10 
(36%) of 28 patients in Group II, but in only 2 (8%) of 24 
patients in Group I and only I (4%) of 23 patients in Group 
III (Group II versus Groups I and III, p < 0.005). 
Hemodynamic effects of nitroglycerin in Group II 
(Table 4). Nine patients in Group II received nitroglycerin 
0.4 mg sub lingually 30 to 60 minutes after the assessment 
of the responses to long-term captopril therapy. Compared 
with the immediate pretreatment hemodynamic state (30 to 
60 minutes after peak captopril effect), nitroglycerin sig-
nificantly decreased (within 10 minutes) right and left ven-
tricular filling pressures, mean systemic and pulmonary ar-
tery pressures and pulmonary and systemic vascular resistances 
(p < 0.05 to p < 0.01). Compared with the hemodynamic 
state observed at peak captopril effect, however, only the 
decrease in mean pulmonary artery pressure (p < 0.05) and 
pulmonary arteriolar resistance (p < 0.01) was significant, 
and this pulmonary vascular response occurred without 
changes in other hemodynamic variables. 
Discussion 
The findings of the present study indicate that changes 
in pulmonary arteriolar resistance play an important role in 
determining the long-term hemodynamic and clinical re-
JACC Vol. 6, NO.3 
September 1985:635-45 
PACKER ET AL. 641 
PULMONARY VASODILATION IN HEART FAILURE 
Table 4. Hemodynamic Responses to Nitroglycerin in Patients in Group II (n = 9) 
C-LT Versus 
Pre-C C-DI C-LT Pre-N Post-N Pre-Versus Post-N Post-N 
CI 1.72 1.91 1.96 I.S1 2.05 NS NS 
(liters/min per m2) ±0.18 ±O.IS ±O.IS ±0.16 ±0.14 
MAP 84.2 67.0* 61.6* 69.3* 59.4* P < 0.01 NS 
(mmHg) ±5.4 ±4.5 ±4.S ±5.1 ±4.1 
LVFP 24.8 15.7* 11.3* 15.1 * 9.0* P < 0.05 NS 
(mmHg) ±J.3 ±2.3 ±3.3 ±2.8 ±2.7 
MPAP 36.8 28.1* 23.0* 27.6* 19.0* P < 0.01 P < 0.05 
(mmHg) ±J.3 ±2.6 ±2.7 ±2.9 ±3.S 
MRAP 10.8 8.0t 6.0* 7.3* 4.6* P < 0.05 NS 
(mmHg) ± 1.1 ±0.9 ±J.7 ± 1.8 ±1.4 
HR 84.9 80.7 74.2* 76.1 * 73.8* NS NS 
(beats/min) ±3.7 ±3.0 ±3.6 ±3.S ±2.S 
SVR 2,152 1,554* 1,437* 1,709* 1,316* P < 0.01 NS 
(dynes's'cm -5) ±202 ± ISS ± 164 ± 169 ± 119 
PAR 368 340 333 353 247* P < 0.01 P < 0.01 
(dynes's'cm- 5) ±45 ±35 ±43 ±46 ±40 
Symbols indicate significance from pre-captopril values: *p < 0.01, tp < 0.05. The last two columns indicate significance between columns by 
analysis of variance. Pre-C = pre-captopril; C-DI = first dose of captopril; C-LT = long-term captopril therapy; Pre-N = before nitroglycerin (30 to 
60 minutes after C-LT); Post-N = after nitroglycerin; other abbreviations as in Table 2. 
sponses to captopril therapy in patients with severe chronic 
left ventricular failure. Despite similar decreases in left ven-
tricular filling pressure and systemic vascular resistance, 
patients who showed substantial pulmonary vasodilation 
(Group I) experienced greater increases in cardiac index, 
stroke volume index and left ventricular stroke work index 
than did patients who demonstrated predominant systemic 
vasodilation (Group II); similarly, right ventricular stroke 
work index was preserved at a lower right ventricular filling 
pressure in patients in Group I than in those in Group II. 
Although both groups improved clinically, patients in whom 
pulmonary arteriolar resistance decreased during converting 
enzyme inhibition had less dramatic decreases in systemic 
blood pressure (and thus experienced less symptomatic hy-
potension) and had a greater decrease in body weight during 
treatment (presumably due to a drug-induced natriuresis) 
than did patients who showed primarily systemic vasodilator 
effects and in whom sodium excretion may have been lim-
ited by the hypotensive effects of the drug (28,29); this 
natriuresis may have contributed significantly to the sub-
stantial decrease in central venous pressures seen in patients 
in Group I. These data strongly support the concept that the 
pulmonary circulation modulates changes in both right and 
left ventricular performance during vasodilator therapy in 
patients with left heart failure. 
Role of the pulmonary circulation in left ventricular 
failure. Clinicians have long believed that excessive ele-
vation of systemic vascular resistance is the principal hemo-
dynamic abnormality of patients with congestive heart fail-
ure and is responsible for their depressed left ventricular 
function and the severity of their symptoms. Recent studies 
(10,11) have shown, however, that right ventricular ejection 
fraction and pulmonary arteriolar resistance are important 
determinants of the functional status of patients with left 
heart failure and correlate better with exercise capacity than 
do measures of left ventricular performance. In such pa-
tients, the ability to increase cardiac output during exertion 
is the primary determinant of exercise duration; if this ability 
is limited by heightened pulmonary arteriolar resistance or 
by right ventricular dysfunction, cardiac output may not 
increase sufficiently to meet the metabolic requirements of 
the body, even if systemic vascular resistance decreases 
dramatically (10). Furthermore, systemic vasodilation in the 
absence of pulmonary vasodilation may result in severe 
hypotension. Such hypotensive episodes are well known in 
patients with pulmonary hypertension secondary to obliter-
ative pulmonary vascular disease whose pulmonary vessels 
are unable to respond to systemic vasodilator therapy (25,26); 
our data indicate that similar hemodynamic events may ex-
plain the hypotensive symptoms of patients with left ven-
tricular failure treated with vasodilator drugs. If, on the other 
hand, pulmonary vasodilation does occur during long-term 
therapy, right ventricular performance may improve dra-
matically and result in an increase in cardiac output and 
exercise capacity (I 2). 
Limited pulmonary vasodilator effects of angiotensin 
suppression. A desired goal of vasodilator therapy for pa-
tients with left ventricular failure, therefore, is balanced 
systemic and pulmonary vasodilation. Direct-acting vaso-
dilator drugs (such as nitroprusside and nitrates) decrease 
systemic and pulmonary resistances to a similar degree 
(13-15), but converting enzyme inhibition generally produces 
dilation in the pulmonary circulation far less dramatically 
than it does in the systemic circuit (21,22). These obser-
vations are consistent with the fact that angiotensin is a 
potent systemic vasoconstrictor that exerts little direct action 
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on the pulmonary vessels in physiologic concentrations 
(16,20); thus, neutralization of its effects during captopril 
therapy produces minimal pulmonary vasodilation. Previous 
studies have established the limited pulmonary vascular ef-
fects of captopril during short-term therapy (21,22); the 
present findings extend these observations to long-term 
treatment. These observations may explain why right ven-
tricular stroke work failed to increase during converting 
enzyme inhibition in our 75 patients, even though left ven-
tricular stroke work increased significantly as resistance to 
left ventricular systolic ejection decreased. These discordant 
responses probably account for the greater frequency of 
symptomatic hypotension with captopril compared with other 
vasodilator drugs (l ,21). Furthermore, the limited ability 
of captopril to improve right ventricular function may re-
strict the potential of some patients to benefit from con-
verting enzyme inhibition. Patients with poor right ventric-
ular function do not respond well to captopril therapy (30,31), 
and pretreatment right ventricular function appears to be the 
principal determinant of long-term survival in patients with 
left heart failure treated with converting enzyme inhibitors 
(31,32). 
Mechanisms of pulmonary vasodilation during cap-
topril therapy. The mechanisms just outlined logically ex-
plain why our patients with the highest pretreatment plasma 
renin activity and the lowest serum sodium concentration 
showed the least pulmonary vasodilation during long-term 
therapy with captopril. These patients have the greatest ac-
tivation of the renin-angiotensin system and appear to be 
highly dependent on angiotensin II to support circulatory 
homeostasis (33); interference with angiotensin II forma-
tion, therefore, can be expected to result in dramatic sys-
temic (but not pulmonary) vasodilation and symptomatic 
hypotension (34), the severity of which is likely to be po-
tentiated by the limited pulmonary vascular responses seen 
in this group (25). Such mechanisms, however, fail to ac-
count for the marked and balanced pulmonary and systemic 
vasodilation during long-term therapy with captopril in our 
patients in Group I, who generally had a low plasma renin 
activity. Why should captopril have resulted in dramatic 
hemodynamic and clinical benefits in these patients? Con-
verting enzyme inhibition may produce hemodynamic im-
provement in some patients with low renin heart failure by 
further reducing the low (but potentially still physiologically 
important) levels of circulating angiotensin II (35). If with-
drawal of the actions of angiotensin were the only mecha-
nism of action in these patients, however, we would have 
expected their pulmonary and systemic vasodilator re-
sponses to captopril to be similar to those seen in our high 
renin patients; because the reverse was true, we must pos-
tulate other mechanisms to explain our observations. The 
angiotensin-converting enzyme is also the same enzyme 
responsible for the degradation of endogenous kinins (36), 
which exert potent vasodilating effects by their ability to 
stimulate the production of prostaglandins by the kidney 
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(37,38). Hence, by inhibiting the converting enzyme, cap-
topril may retard kinin metabolism and thereby enhance 
prostaglandin synthesis, which may contribute substantially 
to the circulatory effects of the drug. That these concepts 
have therapeutic significance is supported by clinical data 
showing I) a marked increase in the level of prostaglandin 
E metabolites in the urine of patients with hypertension and 
heart failure treated with captopril (39-41), and 2) at-
tenuation of the effects of captopril in hypertensive patients 
by agents that inhibit prostaglandin synthesis (40). Studies 
by two independent groups of investigators (42,43) have 
concluded that prostaglandins play the major role in me-
diating the therapeutic effects of converting enzyme inhi-
bition in patients with a low plasma renin activity; in con-
trast, arachidonic acid metabolites appear to have little 
significance in patients with marked activation of the renin-
angiotensin system. 
Our findings provide circumstantial support for the hy-
pothesis that prostaglandins may mediate some of the hemo-
dynamic effects of captopril in patients with low renin heart 
failure. In our patients in Group I (predominant pulmonary 
vasodilation) whose average plasma renin activity was only 
3.0 ± 0.6 ng/ml per h, captopril produced marked decreases 
in both pulmonary and systemic vascular resistance, a re-
sponse that is more consistent with the known hemodynamic 
effects of prostaglandin E than the events expected to follow 
interference with the renin-angiotensin system; unlike an-
giotensin II, prostaglandin E (particularly E1) has direct 
actions on the pulmonary circulation (44,45) and produces 
balanced systemic and pulmonary vasodilator effects in pa-
tients with congestive heart failure (46). Furthermore, pro-
duction of prostaglandins by the kidney may contribute sig-
nificantly to the increase in plasma renin activity that follows 
converting enzyme inhibition (43,47), which may explain 
why reactive hyperreninemia was most marked in patients 
with the greatest pulmonary vasodilator responses. The en-
hanced synthesis of renal prostaglandins may serve to po-
tentiate the effects of furosemide (8,43), which may also 
be mediated by prostaglandin E intermediates (48-50); this 
hormonal interaction may account for the diuresis seen in 
patients in Group I. Further research is needed to validate 
these concepts; such studies should include both measure-
ment of prostaglandin metabolites and hemodynamic as-
sessment of the effects of inhibitors of prostaglandin syn-
thesis during treatment with captopril to determine whether 
these hormonal and hemodynamic events correlate with the 
magnitude of pulmonary vasodilation. It is also possible that 
other hormonal events (for example, the reduction in cir-
culating levels of catecholamines and vasopressin that ac-
companies long-term converting enzyme inhibition [51-53]) 
may contribute significantly to the hemodynamic responses 
we observed. 
Limitations of the study. Our findings need to be in-
terpreted in the context of certain precautions and limita-
tions. We attempted to measure changes in vessel tone and 
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caliber in the pulmonary circulation by calculating pulmo-
nary arteriolar resistance, but conventional approaches to 
the measurement of this variable may not be accurate, be-
cause the relation between blood flow and resistance in the 
pulmonary circulation may not be linear (54,55). Further-
more, df4g-induced changes in left atrial pressure may in-
duce secondary alterations in pulmonary arteriolar resistance 
in the absence of any direct pulmonary vasodilating action 
(56,57); this observation is unlikely to have explained the 
different pulmonary vascular responses seen in patients in 
Groups I and II, however, because the groups demonstrated 
similar decreases in left ventricular filling pressure. An in-
crease in pulmonary blood flow (secondary to an increase 
in cardiac output) can itself lower pulmonary resistance by 
the passive recruitment of unused vascular channels rather 
than by a direct active pulmonary vasodilating effect of a 
drug (58). All of these passive components of the pulmonary 
vascular response may interact with active pulmonary va-
sodilation to determine the hemodynamic effects of therapy. 
Despite these complexities, we believe that selective pul-
monary vasodilation can be assumed to have occurred if the 
decrease in resistance in the pulmonary circulation exceeds 
that seen in the systemic circulation; this generally occurs 
when pulmonary arteriolar resistance decreases simulta-
neously with an increase in cardiac output and a decrease 
in mean pulmonary artery pressure (27). Because the changes 
in all three variables were greater in patients in Group I 
(predominant pulmonary vasodilation) than in Group II (pre-
dominant systemic vasodilation), we believe that the greater 
decrease in pulmonary arteriolar resistance in patients in 
Group I was the result of active pulmonary vasodilation, a 
response that is difficult to explain on the basis of angio-
tensin II suppression alone. 
We considered the possibility that our patients in Group 
II (predominant systemic vasodilation) did not show an ac-
tive pulmonary vasodilator response during treatment with 
captopril because they had fixed structural disease of the 
pulmonary vasculature. Such pulmonary vascular oblitera-
tion may occur in patients who have long-standing increases 
in pulmonary venous pressure (with secondary fibrosis and 
hemosiderosis), particularly in those with severe mitral ste-
nosis. The degrees of elevation of pulmonary arteriolar re-
sistance in Groups I and II, were similar, however; we would 
have anticipated higher levels of pulmonary resistance for 
similar levels of left ventricular filling pressure if additional 
structural changes in the pulmonary vessels had developed 
in patients in Group II. Most important, the selective de-
crease in pulmonary arteriolar resistance after nitroglycerin 
administration in our patients in Group II strongly supports 
our hypothesis that the increased pulmonary resistance in 
these patients was the result of active pulmonary vasocon-
striction that was still responsive to vasodilator therapy (Ta-
ble 4). 
Finally, it is possible that patients in Group II did not 
show substantial pulmonary vasodilation because treatment 
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with captopril activated endogenous vasoconstrictor forces 
that selectively antagonized the pulmonary vasodilation that 
might have been expected to accompany any drug-induced 
decrease in left ventricular filling pressures. The activation 
of such forces has been shown to limit the systemic effect 
of other vasodilator drugs in patients with severe chronic 
heart failure (59,60). There is little evidence, however, that 
such forces are activated during long-term treatment with 
captopril. Circulating levels of both catecholamines and va-
sopressin decrease during long-term captopril therapy (51-53); 
these additional hormonal changes may contribute signifi-
cantly to the hemodynamic improvement as well as to the 
decreases in heart rate and the correction of hyponatremia 
that follow the converting enzyme inhibition in these pa-
tients (8,9). Furthermore, neither norepinephrine nor va-
sopressin is known to selectively constrict the pulmonary 
vasculature. Consequently, selective reflex vasoconstriction 
is an unlikely explanation for our findings. 
Conclusions. The present study indicates that the pul-
monary circulation plays an important role in modifying the 
hemodynamic responses seen during long-term angiotensin-
converting enzyme inhibition in patients with severe chronic 
heart failure. Patients with hyponatremia and a high plasma 
renin activity generally show little long-term pulmonary 
vasodilator response to captopril; therefore, because the pa-
tients' ability to increase cardiac output is limited, clinical 
and hemodynamic benefits are achieved at the cost of fre-
quent episodes of symptomatic hypotension. On the other 
hand, some patients with low renin heart failure show marked 
pulmonary vasodilator effects during treatment that dra-
matically el1hance the improvement in left ventricular per-
formance that might be expected to accompany any drug-
induced decrease in systemic vascular resistance without 
additional hypotensive risk; such pulmonary vasodilator ef-
fects are difficult, however, to explain on the basis of an-
giotensin suppression alone. These observations suggest that 
some patients with severe chronic heart failure may benefit 
from long-term captopril therapy through mechanisms in-
dependent of interference with the renin-angiotensin system. 
We are indebted to the nurses of the Ames and Rose Cardiac Care Units 
of the Mount Sinai Hospital for the excellent care they provided for the 
patients in this study. 
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